Summary
Vertex Pharmaceuticals (VRTX) announced a significant licensing agreement with Janssen Pharmaceuticals, Inc. on June 12, 2014, for the development and commercialization of its novel influenza medicine, VX-787, and a backup compound, VX-353. This deal represents a strategic move for Vertex, allowing it to leverage Janssen's expertise and global reach while mitigating development costs and risks associated with bringing a new drug to market. The agreement involves an upfront payment to Vertex and potential future milestone payments and royalties, providing immediate financial benefit and a path to long-term revenue generation.
Key Highlights
- 1Vertex entered into a material definitive agreement with Janssen Pharmaceuticals, Inc. on June 13, 2014.
- 2Janssen has been granted an exclusive worldwide license to develop and commercialize VX-787, an influenza medicine discovered by Vertex.
- 3Vertex will receive an upfront payment of $30.0 million from Janssen.
- 4The agreement also includes potential future development and commercial milestone payments, as well as royalties on any future product sales.
- 5Janssen will assume responsibility for all costs related to the development and commercialization of VX-787 and VX-353.
- 6The transaction is subject to the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.